switching from semaglutide to tirzepatide Tirzepatide: What to Expect — Affinity Whole Health Maintenance therapy on semaglutide or

It is not formulated for diagnostic or therapeutic implementation

Phase Low-moderate Daily dose 20-50 mcg/day Site Trained muscle, post-workout Notes Often used in research interest in localized hypertrophy signaling

Description CJC 1295 No Dac (5mg) + Ipamorelin (10mg) Blend Calculation: One pen contains 300 units of 50mcg (16.7mcg CJC No DAC and 33.3 mcg Ipamorelin) Examples of calculated units per pen of CJC 1295 No DAC (5 mg) + Ipamorelin (10 mg) BLEND corresponding to micrograms: 1 unit = 16.7 mcg CJC No DAC and 33.3 mcg Ipamorelin

Protocol Details BPC-157 and TB-500 are administered via subcutaneous injection, typically on a daily or alternating-day schedule depending on the severity of the condition